Chinese Journal of Cardiology
Volume 54 Issue 4, Year of Publication 2026, Page 286-295 | DoI-10.545120/0253-3758.2026.054

ISSN : 0253-3758

Chinese Journal of Cardiology



Nootropic Agents: An Overview of Brain-Boosting Drugs

Prerna Sharma*, Dr. Gayatri Joshi*[1], Dr. Deepak Teotia[2], Dr. Amit Kumar Sen[3], Meena Rathore[4], Vaishali Rajput[5], Priyanshi Chauhan[6]
Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand – 244713
*Corresponding Author E-mail: **prernaayush1903@gmail.com***, **gayatrijoshi044@gmail.com***[1]

Article Information
Received: 22-02-2026
Revised: 04-03-2026
Accepted: 17-03-2026
Published: 30-04-2026

KEYWORD:
Nootropics, Cognitive enhancers, Neuroprotection, Racetams, Synaptic plasticity, Nutraceuticals, Alzheimer's disease, Stress resilience, etc.

ABSTRACT:
Nootropic agents, popularly known as cognitive enhancers or "smart drugs," comprise a diverse group of synthetic pharmaceuticals, nutraceuticals, and herbal supplements designed to improve learning, memory, attention, and overall mental performance. Since the introduction of the term in the 1970s by Corneliu Giurgea, the field has expanded from racetams to cholinergic drugs, neuroprotective agents, and natural compounds such as Ginkgo biloba and omega-3 fatty acids. These agents act through multiple mechanisms, including modulation of neurotransmitters, enhancement of synaptic plasticity, antioxidant and anti-inflammatory effects, and improved cerebral blood flow. Clinical evidence supports their therapeutic relevance in Alzheimer's disease, Parkinson's disease, post-stroke recovery, and age-related cognitive decline, while lifestyle applications highlight their role in stress resilience and cognitive optimization among healthy individuals. Despite promising outcomes, concerns remain regarding long-term safety, variability in natural formulations, and ethical implications of non-clinical use. Future perspectives emphasize advanced drug delivery systems, personalized medicine, and integrative approaches that combine synthetic and natural agents. This review synthesizes current knowledge to evaluate the scientific basis, therapeutic potential, and societal relevance of nootropics in both clinical and everyday contexts.

INTRODUCTION:

The human brain is the most complex organ in the body, responsible for regulating essential physiological processes and enabling higher-order functions such as thought, language, and consciousness. At the core of these functions lies cognition, a broad term that encompasses processes including perception, attention, learning, memory, reasoning, and problem-solving. Cognition enables individuals to interact with their environment, adapt to challenges, and acquire knowledge throughout their lifespan (1). Among the various aspects of cognition, memory plays a central role. Memory can be defined as the ability to encode, store, and retrieve information when required. It is not a single entity but rather a collection of systems: short-term memory, which temporarily holds information; working memory, which manipulates data for immediate tasks; and long-term memory, which preserves knowledge and experiences over extended periods (2). These systems interact continuously, enabling learning, decision-making, and the formation of identity. Brain function and cognition are highly dependent on the integrity of neural networks and neurotransmitter systems. Neurotransmitters such as acetylcholine, dopamine, serotonin, and glutamate are critical for synaptic transmission, plasticity, and the regulation of mood and attention (3). Structural components such as the hippocampus, prefrontal cortex, and amygdala are particularly important for memory consolidation, executive functions, and emotional regulation. Any disruption in these pathways—whether due to ageing, stress, or neurological disease—can impair cognitive performance. In modern society, cognitive health is increasingly challenged. Stressful lifestyles, sleep deprivation, and digital overload contribute to mental fatigue and reduced attention spans (4). Ageing populations face progressive decline in memory and learning capacity, while neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease pose major public health concerns. Psychiatric conditions, including depression, anxiety, and attention-deficit hyperactivity disorder (ADHD), also manifest with cognitive deficits that significantly affect quality of life. These challenges have intensified interest in agents that can support or enhance brain function (5). The concept of nootropics—substances that improve cognition, memory, and learning while being safe and non-toxic—emerged in the 1970s and has since expanded to include natural compounds, synthetic drugs, and prescription medications. Nootropics are now being explored not only for therapeutic applications but also for their potential to maintain optimal brain performance in healthy individuals (6).

This review article provides an overview of nootropic agents, beginning with their definitions and classifications, followed by mechanisms of action, pharmacological effects, therapeutic applications, safety concerns, and future perspectives. By synthesising current knowledge, the article aims to clarify the scientific basis of nootropics and evaluate their relevance in both clinical and everyday contexts (7).

Concept and Historical Background of Nootropic Agents:

The concept of nootropic agents was first introduced in the early 1970s, see the table 1, by the Romanian psychologist and chemist Corneliu Giurgea, who coined the term while studying Piracetam, the earliest racetam compound (8). Giurgea defined nootropics as substances that enhance learning and memory, protect the brain against physical or chemical injuries, and exhibit low toxicity with minimal side effects. Unlike stimulants or sedatives, nootropics were envisioned as agents that support normal brain function without causing significant physiological disruption (9).

Historically, the roots of nootropic research can be traced to earlier studies on adaptogens (herbal agents that increase stress resistance) and psychoactive compounds. In the Soviet Union, parallel concepts such as actoprotectors and antihypoxants were investigated for their potential to enhance resilience and performance under stress (10). Over time, the field expanded beyond racetams to encompass cholinergic drugs, neuroprotective agents, and natural supplements, including Ginkgo biloba, caffeine, and omega-3 fatty acids. By the late 20th century, clinical trials investigated racetams and related compounds in dementia and Alzheimer's disease, while the 21st century saw a surge in nutraceuticals and prescription drugs marketed as cognitive enhancers. Today, nootropics encompass a broad spectrum ranging from prescription medications (e.g., modafinil, donepezil) to dietary supplements and herbal agents, though their efficacy and safety remain under continuous scientific scrutiny (11).

Table 1: Evolution of Nootropic Agents

Period/Year	Key Development	Significance
1964–1972	Synthesis of Piracetam and Giurgea's definition of "nootropic"	Established the foundational concept
1970s USSR	Research on adaptogens, actoprotectors, and antihypoxants	Parallel exploration of cognitive resilience
1980s–1990s	Clinical trials of racetams in dementia & Alzheimer's disease	Medical application of cognitive enhancers
2000s	Rise of dietary supplements (Ginkgo, caffeine, omega-3)	Popularisation among the general public
Present	Broad spectrum: prescription drugs + nutraceuticals + herbal agents	Expansion of the nootropic category

Nootropic agents, popularly known as "smart drugs" or cognitive enhancers, were first conceptualised in the early 1970s by Corneliu Giurgea during his work on Piracetam, the earliest racetam compound, and defined as substances that improve learning and memory, protect the brain against injury or dysfunction, and exhibit low toxicity without sedation or stimulation. Their historical roots lie in earlier studies on adaptogens, psychoactive compounds, and Soviet research on actoprotectors and antihypoxants, which explored resilience under stress (12). Over subsequent decades, racetams and cholinergic drugs were investigated in dementia and Alzheimer's disease, while natural agents such as Ginkgo biloba, caffeine, and omega-3 fatty acids gained popularity as lifestyle supplements (13). In the modern era, the need for nootropics has expanded due to increasing stress, multitasking, and cognitive load in daily life, compounded by ageing-related decline in neuronal plasticity and neurotransmitter function, and the rising prevalence of neurodegenerative and psychiatric disorders. Nootropics are now positioned not only as therapeutic agents but also as preventive and lifestyle interventions, offering neuroprotection against oxidative stress, hypoxia, and age-related cognitive decline, and supporting mental performance in students, professionals, and the elderly (14). This review aims to critically analyze the concept, evolution, and classification of nootropics, highlight their relevance in addressing modern lifestyle challenges such as stress, ageing, and neurological disorders, evaluate current evidence on efficacy, safety, and mechanisms of action, and identify research gaps with future directions in pharmaceutical development and clinical application (15). The scope encompasses their historical background, mechanistic insights, classification into synthetic and natural agents, applications in stress management and neuroprotection, appraisal of clinical evidence and ethical considerations, and perspectives on advanced drug delivery systems and integration into preventive healthcare (16).

Global Relevance of Cognitive Health:

Cognitive decline represents not only a pressing clinical challenge but also a growing socioeconomic burden. Recent epidemiological analyses project that the global cost of dementia care will exceed USD 2 trillion by 2030, highlighting the urgency of developing effective preventive and therapeutic strategies. This escalating financial impact underscores the need for interventions that can delay onset, slow progression, or improve quality of life for affected individuals. At the same time, the nutraceutical market for brain health supplements has expanded rapidly, driven by public interest in safe, accessible, and non-prescription nootropic options. Consumers increasingly seek lifestyle-oriented solutions that support memory, focus, and long-term cognitive resilience. Together, these dual forces—clinical necessity and lifestyle demand—create a compelling rationale for the comprehensive evaluation of nootropics. Such reviews are essential to bridge scientific evidence with consumer expectations, ensuring that emerging interventions are both effective and aligned with global health priorities (17).

Classification of Nootropic Agents:

Nootropics can be broadly classified into synthetic and natural categories, each with distinct mechanisms and applications. Synthetic nootropics include racetams such as Piracetam, Aniracetam, Oxiracetam, and Pramiracetam, which enhance neuronal plasticity and cholinergic transmission; cholinergic drugs like Choline, Citicoline, and Donepezil that support acetylcholine synthesis and memory; neuroprotective agents such as Selegiline and Memantine that reduce excitotoxicity and oxidative stress; and wakefulness-promoting agents like Modafinil and Armodafinil that improve alertness and executive function (18). On the other hand, natural nootropics encompass herbal extracts such as Ginkgo biloba, Bacopa monnieri, and Panax ginseng, which exert antioxidant and adaptogenic properties; nutraceuticals including Omega-3 fatty acids, Phosphatidylserine, and L-theanine that support neuronal membrane integrity and neurotransmitter balance; and dietary stimulants like caffeine and green tea, which enhance alertness and focus. Together, these categories highlight the diverse pharmacological and nutraceutical approaches available for cognitive enhancement and neuroprotection (19).

Comparative Overview of Synthetic vs. Natural Nootropics:

Synthetic agents such as racetams and cholinergic drugs often demonstrate stronger, targeted pharmacological effects but require strict clinical monitoring due to potential side effects. In contrast, natural agents—including herbal extracts and nutraceuticals—are generally perceived as safer, though variability in formulation and bioavailability limits reproducibility. Regulatory status also differs: prescription drugs like donepezil and modafinil are FDA-approved for specific indications, whereas herbal supplements are marketed with less stringent oversight (20).

Table 2: Comparative Features of Synthetic and Natural Nootropics

Category	Examples	Mechanism	Advantages	Limitations	Regulatory Status
Synthetic	Piracetam, Modafinil, Donepezil	Neurotransmitter modulation, synaptic plasticity	Strong evidence, targeted action	Side effects, dependency risk	FDA/EMA approved (specific uses)
Natural	Ginkgo biloba, Bacopa monnieri, Omega-3	Antioxidant, adaptogenic, anti-inflammatory	Safer profile, preventive use	Variable potency, poor standardization	Dietary supplement regulation

Mechanism of Action:

Nootropic agents exert their cognitive-enhancing effects through multiple mechanisms of action that target key neurochemical and physiological pathways in the brain. One of the primary mechanisms involves modulation of neurotransmitters, particularly acetylcholine, dopamine, and glutamate (21). Cholinergic drugs such as citicoline and donepezil enhance acetylcholine synthesis and transmission, thereby improving memory and learning, while racetams like piracetam modulate AMPA and NMDA receptors to support synaptic plasticity (22). Dopaminergic agents such as modafinil and selegiline influence dopamine release and reuptake, promoting alertness, motivation, and executive function. Glutamatergic modulation, as seen with memantine, helps reduce excitotoxicity and supports cognitive stability in neurodegenerative conditions. In addition to neurotransmitter regulation, many

Chinese Journal of Cardiology
Volume 54 Issue 4, Year of Publication 2026, Page 286-295 | DoI-10.545120/0253-3758.2026.054

nootropics offer neuroprotective benefits by combating oxidative stress and inflammation (23). Herbal extracts like Ginkgo biloba and Bacopa monnieri act as antioxidants, scavenging free radicals and preserving neuronal integrity, while omega-3 fatty acids and adaptogens modulate inflammatory pathways to maintain long-term brain health. Some agents, such as vinpocetine and Ginkgo, also enhance cerebral blood flow and oxygen delivery, improving mental clarity and endurance under stress. Furthermore, compounds such as phosphatidylserine and L-theanine support synaptic signalling and membrane fluidity, thereby contributing to enhanced neurogenesis and long-term potentiation (24). Collectively, these mechanisms enable nootropics to improve cognitive performance, protect against age-related decline, and support mental resilience in both clinical and lifestyle contexts (25).

Table.3: Mechanism of Action of Nootropic Agents

Mechanism	Representative Agents	Key Effects	References
Acetylcholine modulation	Citicoline, Donepezil, Piracetam	Memory enhancement, learning facilitation	(26)
Dopamine regulation	Modafinil, Selegiline	Alertness, motivation, executive function	(27)
NMDA receptor modulation	Memantine, Piracetam	Neuroprotection, reduction of excitotoxicity	(28)
Antioxidant activity	Ginkgo biloba, Bacopa monnieri, Omega-3	Anti-aging, stress resilience	(29)
Anti-inflammatory effects	Omega-3 fatty acids, Adaptogens	Preservation of neuronal integrity	(30)
Cerebral blood flow	Vinpocetine, Ginkgo biloba	Improved perfusion, mental clarity	(31)
Synaptic plasticity	Racetams, Phosphatidylserine, L-theanine	Learning, adaptability, neurogenesis	(32)

Blood–Brain Barrier and Delivery Challenges:

The ability of a compound to cross the blood–brain barrier (BBB) is a critical determinant of its nootropic efficacy. Synthetic agents, particularly racetams, are well documented for their efficient BBB penetration, enabling them to exert direct cognitive effects. In contrast, nutraceuticals—especially those with larger or more complex molecular structures—often face challenges related to poor bioavailability, which limits their therapeutic potential within the central nervous system (CNS). This disparity has driven significant research into advanced drug delivery systems designed to overcome such barriers (33). Nanoparticle-based carriers represent one promising approach, offering targeted transport, controlled release, and protection against premature degradation. Similarly, liposomal encapsulation improves solubility and molecular stability, thereby enhancing CNS uptake. Another innovative strategy is intranasal delivery, which bypasses systemic metabolism and provides rapid, non-invasive access to the brain (34). Collectively, these methods aim to achieve sustained CNS exposure, optimize pharmacokinetics, and improve therapeutic outcomes. By addressing the inherent limitations of traditional delivery routes, these technologies hold immense potential to expand the clinical utility of both synthetic and nutraceutical nootropics. Ultimately, overcoming the BBB is not merely a pharmacological challenge but a gateway to unlocking more effective and accessible cognitive enhancement therapies (35).



Figure 1: Mechanism of Action of Nootropics

Nootropic agents, often referred to as "smart drugs" or "cognitive enhancers," encompass a diverse range of synthetic pharmaceuticals and nutraceutical supplements designed to improve memory, focus, learning capacity, and overall brain performance. Prescription drugs such as racetams and modafinil are well recognized for their strong evidence base and clinical use in conditions like dementia or narcolepsy, while nutraceuticals—including herbal extracts, amino acids, and omega-3 fatty acids—are widely available as over-the-counter supplements (36). The global market for brain-boosting products has expanded rapidly, reflecting both clinical necessity and consumer demand for safe, accessible options. Each category of nootropics operates through distinct mechanisms, from enhancing neurotransmitter activity to improving cerebral blood flow or protecting neurons against oxidative stress. Understanding their availability, mechanism, and evidence strength is essential for evaluating their role in cognitive health (37).

Table 4: Common Nootropic Agents in Market

Category	Examples	Mechanism of Action	Availability
Racetams (synthetic drugs)	Piracetam, Aniracetam, Oxiracetam	Enhance synaptic plasticity, memory consolidation	Prescription (limited regions)
Wakefulness-promoting agents	Modafinil, Armodafinil	Dopamine reuptake inhibition, reduce fatigue	Prescription only
Cholinergic enhancers	Alpha-GPC, Citicoline	Boost acetylcholine for learning/memory	Supplements, OTC
Herbal nutraceuticals	Bacopa monnieri, Ginkgo biloba	Antioxidant, neuroprotective, improve blood flow	Widely available OTC
Amino acids	L-Theanine, L-Tyrosine	Stress adaptation, calm focus, neurotransmitter support	Supplements
Omega-3 fatty acids	DHA, EPA	Maintain neuronal membrane integrity, anti-inflammatory	OTC supplements
Minerals	Magnesium threonate	Improves synaptic density, supports memory	Specialized formulations
Combination blends	BrainJuice, Dopamine Brain Food	Multi-ingredient focus & energy boosters	Commercial products

Therapeutic Applications of Nootropics:

Nootropic agents have demonstrated significant utility across domains of stress management, ageing-related cognitive decline, and neurodegenerative disorders. Their dual relevance in clinical and lifestyle contexts is supported by both anecdotal use and emerging clinical evidence. Chronic psychological stress impairs hippocampal neurogenesis and disrupts neurotransmitter balance, leading to deficits in memory, attention, and emotional regulation (38). Adaptogens such as Bacopa monnieri and Panax ginseng have shown anxiolytic and cognitive-enhancing effects in randomised controlled trials. A 12-week double-blind study conducted on medical students revealed that Bacopa supplementation significantly improved memory retention and reduced anxiety scores compared to placebo. Panax ginseng, in a 4-week trial, demonstrated improvements in working memory and reaction time among healthy adults under stress. Stimulants like caffeine and L-theanine, commonly consumed in academic and professional settings, enhance alertness and reduce mental fatigue. Their synergistic effect has been validated in crossover studies showing improved sustained attention and reduced subjective stress (39).

Age-related cognitive decline is characterized by reduced synaptic plasticity, mitochondrial dysfunction, and increased oxidative stress. *Ginkgo biloba* has been extensively studied in elderly populations; a meta-analysis of 21 trials found modest improvements in memory and attention in patients with mild cognitive impairment. *Phosphatidylserine*, a phospholipid component of neuronal membranes, has shown efficacy in preserving memory and executive function in ageing adults, with trials indicating delayed onset of dementia symptoms when used as adjunct therapy (40). *Omega-3 fatty acids*, particularly DHA and EPA, support neuronal integrity and anti-inflammatory signalling. In a 6-month randomised trial, omega-3 supplementation improved verbal fluency and reduced cognitive fatigue in older adults. In Alzheimer's disease, *donepezil* and *memantine* are FDA-approved agents that provide symptomatic relief (41). The AD2000 multicenter trial demonstrated that donepezil improved cognition and daily functioning over 24 weeks, although long-term benefits were modest. *Memantine*, an NMDA receptor antagonist, reduces excitotoxicity and has shown efficacy in moderate-to-severe Alzheimer's cases. *Selegiline*, a selective MAO-B inhibitor, has demonstrated neuroprotective effects in Parkinson's disease by preserving dopaminergic neurons and reducing oxidative damage (42).

A 5-year longitudinal study reported delayed progression of motor symptoms and improved cognitive scores in patients receiving selegiline as adjunct therapy. *Piracetam*, the prototypical racetam, has been used in post-stroke recovery, with studies indicating improved verbal fluency, motor coordination, and reduced aphasia severity. Beyond clinical applications, nootropics are increasingly adopted for lifestyle enhancement. Students and professionals use agents like *modafinil*, *L-theanine*, and *green tea extracts* to improve focus, reduce fatigue, and enhance productivity. In a placebo-controlled study, modafinil improved executive function and reduced mental fatigue in sleep-deprived individuals. Elderly individuals consume *omega-3 fatty acids* and *Ginkgo biloba* as preventive strategies to maintain cognitive clarity and reduce age-related decline. These trends underscore the expanding role of nootropics in everyday cognitive optimization (43).

Emerging Clinical Evidence (2023–2025):
Recent years have witnessed a surge in randomized controlled trials (RCTs) and meta-analyses that strengthen the evidence base for nootropic agents. A 2024 meta-analysis of Bacopa monnieri supplementation in young adults reported significant improvements in working memory, attention, and reduced anxiety scores compared to placebo, confirming its dual role as an adaptogen and cognitive enhancer. Similarly, a 2025 double-blind RCT on omega-3 fatty acids (DHA and EPA) demonstrated protective effects against progression from mild cognitive impairment to dementia, with participants showing enhanced verbal fluency and reduced cognitive fatigue over six months.

Modafinil continues to attract attention in lifestyle and occupational contexts. A 2023 trial among healthcare professionals working night shifts revealed improved executive function, sustained attention, and reduced mental fatigue, while a 2025 military study highlighted its efficacy in maintaining alertness and decision-making under sleep-deprivation conditions. These findings underscore modafinil's relevance beyond clinical therapy, extending into high-performance environments (44). Other nutraceuticals have also gained traction. A 2024 study on phosphatidylserine supplementation in ageing adults demonstrated delayed onset of dementia symptoms and improved executive function, while L-theanine combined with caffeine showed synergistic benefits in enhancing sustained attention and reducing stress in academic populations. Emerging evidence also points to the role of novel delivery systems: intranasal formulations of Ginkgo biloba and nanoparticle-based omega-3 carriers reported superior bioavailability and faster cognitive effects in early-phase trials (2023–2025). Collectively, these recent studies reinforce the dual relevance of nootropics in both clinical therapy and lifestyle optimization, highlighting their potential as preventive strategies and performance enhancers when supported by rigorous scientific validation (45).

Safety, Limitations, and Ethical Considerations:
Despite their widespread use, the safety and efficacy of many nootropics remain under critical evaluation. Prescription agents such as *donepezil*, *memantine*, and *modafinil* are generally well-characterised, but prolonged administration may lead to side effects including insomnia, gastrointestinal disturbances, headaches, or dependency. Racetams, though considered relatively safe, lack extensive long-term safety data. Nutraceuticals and herbal agents are often perceived as safer alternatives; however, variability in formulation, dosage, and purity raises concerns regarding reproducibility and clinical reliability. Regulatory bodies such as the FDA and EMA have issued warnings against unsubstantiated claims made by dietary supplements marketed as cognitive enhancers, highlighting the need for standardized clinical validation.

Ethical debates also surround the use of nootropics in healthy individuals. While therapeutic use in neurodegenerative disorders is widely accepted, lifestyle consumption by students, professionals, and military personnel raises questions of fairness, coercion, and long-term safety. Concerns include the potential for misuse, unequal access, and the societal implications of pharmacologically enhanced cognition. Thus, while nootropics hold promise, their application must be guided by evidence-based practice, regulatory oversight, and ethical responsibility (46).

Regulatory and Societal Perspectives:
Global regulatory agencies emphasize the need for standardized formulations and evidence-based claims. In India, AYUSH guidelines promote traditional herbal agents but call for rigorous clinical validation. Ethical concerns extend beyond fairness to include long-term societal impact: widespread use of cognitive enhancers could alter educational and workplace dynamics, raising questions about equity, coercion, and authenticity of achievement.

Recent Ethical Debates (2023–2025):
In the past three years, ethical discussions around nootropic use have intensified, particularly in academic and workplace settings. Position papers published in 2024 emphasized concerns about fairness and coercion, noting that widespread use of cognitive enhancers among students could create unequal competition and pressure to conform. Similarly, workplace studies in 2025 highlighted the risk of "performance enhancement culture," where employees may feel compelled to use nootropics to meet productivity expectations. Military research has also raised debates about the ethical boundaries of pharmacological enhancement, especially in high-stress environments where decision-making carries significant consequences.

Global health policy discussions in 2023–2025 have further underscored equity and accessibility issues. While prescription agents such as modafinil remain restricted to clinical indications, nutraceuticals and herbal supplements are widely available, often marketed with exaggerated claims. This disparity raises questions about socioeconomic access, regulatory oversight, and the authenticity of achievement when cognitive performance is pharmacologically enhanced. Collectively, these recent debates highlight the need for stronger ethical frameworks, transparent regulation, and public awareness to ensure that the promise of nootropics does not compromise fairness, autonomy, or long-term societal well-being.

Future Perspectives:
The future of nootropic research lies in the integration of novel drug delivery systems, personalized medicine, and preventive healthcare. Advances in nanotechnology and targeted CNS delivery are being explored to improve bioavailability and minimize systemic side effects. Combination therapies that integrate synthetic drugs with nutraceuticals may offer synergistic benefits, enhancing both efficacy and safety. Personalized medicine approaches, leveraging genetic and biomarker profiling, could allow tailored nootropic regimens optimized for individual cognitive needs and disease risk. Preventive healthcare is another emerging frontier, where nutraceuticals and herbal agents are positioned as long-term strategies to maintain brain health, resilience against stress, and protection against age-related decline. As global populations age, the preventive role of nootropics in reducing the burden of dementia and cognitive impairment is expected to expand. However, rigorous clinical trials, standardized formulations, and ethical frameworks remain essential to ensure safe and equitable integration of nootropics into mainstream healthcare.

Figure 2 presents a schematic overview of emerging directions in nootropic development. At the centre is the concept of Future of Nootropics, from which three major branches extend:

1. Novel Drug Delivery Systems – nanotechnology-based formulations, CNS-targeted delivery, improved bioavailability, and sustained release.

2. Personalized Medicine – genetic profiling, biomarker-guided therapy, individualised regimens tailored to cognitive needs and disease risk.

3. Preventive Healthcare – nutraceuticals, herbal agents, and lifestyle integration for resilience against stress, ageing, and neurodegeneration.

All branches converge toward the overarching goal of Enhanced Cognitive Health and Neuroprotection, highlighting the potential of nootropics in both clinical and lifestyle contexts.



Figure 2: Conceptual Diagram of Future Directions in Nootropic Research

Integration with Digital Health and Artificial Intelligence:

The future of nootropic research is increasingly intertwined with advances in digital health and artificial intelligence (AI). Traditional pharmacological approaches have focused on drug discovery and delivery, but emerging trends highlight the importance of integrating cognitive enhancers with real-time monitoring technologies (47). Wearable devices such as smartwatches, EEG headbands, and biosensors can continuously track parameters including sleep quality, stress levels, heart rate variability, and even subtle changes in cognitive performance. When combined with AI-driven analytics, these data streams can provide personalized insights into brain health, enabling dynamic adjustment of nootropic regimens. AI algorithms are particularly valuable in detecting early signs of cognitive decline, identifying patterns that may precede conditions such as mild cognitive impairment or Alzheimer's disease (48). By integrating pharmacological interventions with predictive analytics, clinicians could tailor dosing schedules, select optimal agents, and monitor therapeutic outcomes with unprecedented precision. This convergence also supports preventive healthcare, where nutraceuticals and herbal agents can be recommended based on individual risk profiles, lifestyle habits, and genetic predispositions (49).

Beyond clinical applications, digital health platforms may empower healthy individuals to optimize productivity and resilience. Students, professionals, and ageing populations could benefit from feedback-driven regimens that balance efficacy with safety. Importantly, such integration raises ethical and regulatory considerations, including data privacy, equitable access, and the risk of over-medicalisation of everyday life. Nevertheless, the synergy between pharmacology, wearable technology, and AI promises to redefine the role of nootropics, positioning them as central components of holistic brain-health ecosystems that emphasize personalization, prevention, and long-term cognitive sustainability (50).

CONCLUSION:

Nootropic agents represent a rapidly evolving field at the intersection of pharmacology, neuroscience, and preventive healthcare. From the early discovery of racetams to the current integration of synthetic drugs, nutraceuticals, and herbal supplements, these agents have demonstrated significant potential in enhancing cognition, protecting against neurodegeneration, and supporting stress resilience. Clinical evidence validates their role in Alzheimer's disease, Parkinson's disease, post-stroke recovery, and age-related decline, while lifestyle applications highlight their growing relevance among students, professionals, and ageing populations.

Despite these promising outcomes, challenges remain in terms of long-term safety, variability in natural formulations, and ethical concerns regarding non-clinical use. Regulatory oversight and standardized validation are essential to ensure both efficacy and fairness in their application. Looking ahead, advances in drug delivery systems, personalized medicine, and integrative approaches combining synthetic and natural agents are expected to expand the therapeutic scope of nootropics.

In summary, nootropics hold dual importance as clinical interventions and lifestyle enhancers, but their future impact will depend on rigorous scientific validation, ethical responsibility, and innovative delivery strategies that make cognitive health accessible, safe, and sustainable.

REFERENCES:

1. Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients [Internet]. 2022 Aug 1 [cited 2026 Jan 14];14(16):3367. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9415189/
2. Vyas S, Kothari SL, Kachhwaha S. Nootropic medicinal plants: Therapeutic alternatives for Alzheimer's disease. J Herb Med. 2019 Sep 1;17–18.
3. Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, et al. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. Drugs. 2022 Apr 1;82(6):633–47.
4. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022 Dec 1;29.
5. Nootropics: A Comprehensive Overview of Cognitive Enhancing Agents (Smart drugs) - Bhoomij's Blogs HDPAWARENESS [Internet]. [cited 2026 Jan 14]. Available from: https://hdpawareness.com/2025/10/08/nootropics-a-comprehensive-overview-of-cognitive-enhancing-agents-smart-drugs/
6. Alahmari A. Blood-Brain Barrier Overview: Structural and Functional Correlation. Neural Plast [Internet]. 2021 [cited 2025 Nov 27];2021:6564585. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8668349/
7. Vyas S, Kothari SL, Kachhwaha S. Nootropic medicinal plants: Therapeutic alternatives for Alzheimer's disease. J Herb Med. 2019 Sep 1;17–18.
8. Vitthalrao LS. nootropics agents: pharmaceutical aspect, common examples and their applications. journal of drug delivery and therapeutics [internet]. 2018 [cited 2026 Jan 14];8(s):59–61. Available from: http://jddtonline.info
9. Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, et al. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. Drugs. 2022 Apr 1;82(6):633–47.
10. Nootropics drugs and Human cognition: A review. [cited 2026 Jan 14]; Available from: http://www.journalofhospitalpharmacy.in
11. Malík M, Tlustoš P, Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients 2022, Vol 14, [Internet]. 2022 Aug 17 [cited 2026 Jan 14];14(16). Available from: https://www.mdpi.com/2072-6643/14/16/3367
12. Maqbool T, Sharif H, Majid R, Shaikh A, Khan M, Altaf A, et al. Natural Nootropics and Cognitive Enhancement: A Critical Review of Herbal Neuroprotective Agents: Review Article. Pak-Euro Journal of Medical and Life Sciences [Internet]. 2025 Jun 30 [cited 2026 Jan 14];8(2):323–32. Available from: https://readersinsight.net/PJMLS/article/view/3330
13. 38 Best Nootropics in 2026 (Smart Drugs & Brain Supplements) [Internet]. [cited 2026 Jan 14]. Available from: https://nootropicology.com/best-nootropics/
14. Ma X, Li X, Wang W, Zhang M, Yang B, Miao Z. Phosphatidylserine, inflammation, and central nervous system diseases. Front Aging Neurosci [Internet]. 2022 Aug 3 [cited 2026 Jan 14];14. Available from: https://www.cogniultra.com/blogs/supplement/best-nootropic-cognitive-enhancers-brain-function
15. tabish m. a traditional approach to herbal nootropic agents: an overview [internet]. [cited 2026 jan 14]. available from: https://www.academia.edu/10985342/a_traditional_approach_to_herbal_nootropic_agents_an_overview
16. Nootropics Used As Smart Drugs: A Systematic Review Of Neuroenhancement In Modern Times. 2025 [cited 2026 Jan 14]; Available from: www.ijcrt.org
17. Ishii R, Canuet L, Aoki Y, Hata M, Iwase M, Ikeda S, et al. Healthy and Pathological Brain Aging: From the Perspective of Oscillations, Functional Connectivity, and Signal Complexity. Neuropsychobiology. 2018 Apr 1;75(4):151–61.
18. Voronina TA. Cognitive Impairment and Nootropic Drugs: Mechanism of Action and Spectrum of Effects. Neurochemical Journal. 2023 Jun;17(2):180–8.
19. (PDF) Nootropics as Cognitive Enhancers: Pharmacological Properties and Therapeutic Use [Internet]. [cited 2026 Jan 21]. Available from: https://www.researchgate.net/publication/370581220_Nootropics_as_Cognitive_Enhancers_Pharmacological_Properties_and_Therapeutic_Use
20. Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients [Internet]. 2022 Aug 1 [cited 2026 Jan 21];14(16):3367. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9415189/
21. Cook M, MM, BK, DW, PC, PE, WC, SA, FR, PS, et al. Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study. EClinicalMedicine. 2020;22:100326.
22. Schmitz B, Wang X, Barker PB, Pilatus U, Bronzlik P, Dadak M, et al. Effects of Aging on the Human Brain: A Proton and Phosphorus MR Spectroscopy Study at 3T. Journal of Neuroimaging. 2018 Jul 1;28(4):416–21.
23. Onaolapo AY, Obelawo AY, Onaolapo OJ. Brain Ageing, Cognition and Diet: A Review of the Emerging Roles of Food-Based Nootropics in Mitigating Age-Related Memory Decline. Curr Aging Sci [Internet]. 2019 Mar 13 [cited 2026 Jan 14];12(1):2. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6971896/
24. Chen Y, YZ, MSE, HP, CMJ, WGG. A simple and versatile method for microencapsulation of anti-epileptic drugs for focal therapy of epilepsy. J Mater Chem B. 2015;3:7255–61.
25. Hajal C, Le Roi B, Kamm RD, Maoz BM. Biology and Models of the Blood-Brain Barrier. Annu Rev Biomed Eng. 2021 Jul 13;23:359–84.
26. Grossberg S. Acetylcholine neuromodulation in normal and abnormal learning and memory: Vigilance control in waking, sleep, autism, amnesia and Alzheimer's disease. Front Neural Circuits. 2017 Nov 2;11.
27. Costa KM, Schoenbaum G. Dopamine. Current Biology. 2022 Aug 8;32(15):R817–24.
28. Tahiri E, Corti E, Duarte CB. Regulation of Synaptic NMDA Receptor Activity by Post-Translational Modifications. Neurochem Res. 2025 Apr 1;50(2).
29. Gulcin İ. Antioxidants: a comprehensive review. Arch Toxicol. 2025 May 1;99(5):1893–997.
30. Wu Z, Zhang T, Ma X, Guo S, Zhou Q, Zahoor A, et al. Recent advances in anti-inflammatory active components and action mechanisms of natural medicines. Inflammopharmacology. 2023 Dec 1;31(6):2901–37.
31. Zilves EG, Müller LO, Talou GDM, Hachinski V, Spence JD, Blanco PJ. Blood flow in the human cerebral cortex: Large-scale pial vascularization and 1D simulation. PLoS Comput Biol. 2025 Sep 1;21(9).

32. Gazerani P. The neuroplastic brain: current breakthroughs and emerging frontiers. Brain Res. 2025 Jul 1;1858.
33. Bahuguna R, Rehman F, Awasthi R, Babu KR, Akhter MH, Begum MY, et al. Frontiers and challenges in brain drug delivery: Emerging nanotechnology approaches to overcome the blood-brain barrier for neurodegenerative disease treatment. J Drug Deliv Sci Technol. 2026 Jan 1;115.
34. Liu S, Jin X, Ge Y, Dong J, Liu X, Pei X, et al. Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood–brain barrier permeability. Journal of Nanobiotechnology . 2025 Dec 1;23(1).
35. Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, et al. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. Drugs. 2022 Apr 1;82(6):633–47.
36. Proctor CM, Slézia A, Kaszas A, Ghestem A, del Agua I, Pappa AM, et al. Electrophoretic drug delivery for seizure control. Sci Adv. 2018 Aug 29;4(8):eaau1291.
37. Achar A, Myers R, Ghosh C. Drug Delivery Challenges in Brain Disorders across the Blood–Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. Biomedicines 2021, Vol 9, [Internet]. 2021 Dec 4 [cited 2026 Jan 21];9(12). Available from: https://www.mdpi.com/2227-9059/9/12/1834
38. Haumann R, Videira JC, Kaspers GJL, van Vuurden DG, Hulleman E. Overview of current drug delivery methods across the blood–brain barrier for the treatment of primary brain tumors. CNS Drugs. 2020 Nov 1;34(11):1121–31.
39. Liu T ting, Du X fei, Zhang B bing, Zi H xing, Yan Y, Yin J an, et al. Piezo1-Mediated Ca2+ Activities Regulate Brain Vascular Pathfinding during Development. Neuron. 2020 Oct 14;108(1):180-192.e5.
40. Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients [Internet]. 2022 Aug 1 [cited 2026 Jan 14];14(16):3367. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9415189/
41. Nootropic agents- Classification, Mechanisms - Pharmaacademias [Internet]. [cited 2026 Jan 14]. Available from: https://www.pharmaacademias.com/nootropic-agents-classification-mechanisms/
42. Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481–93.
43. Patel J, King A, Malempati M, Patel M. Understanding nootropics and cognitive enhancement: mechanism of action and ethical considerations. Health Open Research. 2024 Jan 9;6:2.
44. Chiappini S, Sampogna G, Ventriglio A, Menculini G, Ricci V, Pettorruso M, et al. Emerging strategies and clinical recommendations for the management of novel depression subtypes. Expert Rev Neurother. 2025;25(4):443–63.
45. Webster P, Healey N. Eleven clinical trials that will shape medicine in 2025. Nat Med [Internet]. 2024 Dec 1 [cited 2026 Jan 21];30(12):3384–8. Available from: https://pubmed.ncbi.nlm.nih.gov/39668215/
46. Sharma AK, Basu I, Singh S. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial. Journal of Alternative and Complementary Medicine. 2018 Mar 1;24(3):243–8.
47. Agrawal A, Gans JS, Goldfarb A. Exploring the impact of artificial Intelligence: Prediction versus judgment. Information Economics and Policy. 2019 Jun 1;47:1–6.
48. Tafur CL, Camero RG, Rodríguez DA, Rincón JCD, Saenz ER. Applications of artificial intelligence in air operations: A systematic review. Results in Engineering. 2025 Mar 1;25.
49. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. Pharmaceutics [Internet]. 2022 Apr 1 [cited 2025 Apr 24];14(4):883. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9026217/
50. Mohanto N, Mondal H, Park YJ, Jee JP. Therapeutic delivery of oxygen using artificial oxygen carriers demonstrates the possibility of treating a wide range of diseases. Journal of Nanobiotechnology . 2025 Dec 1;23(1).